The race to supply obesity drugs is so competitive that one startup is already striking a deal for commercial manufacturing even when its lead candidate is still in early stage testing.
Metsera, a biotech focused on obesity drugs that came out of stealth this year, said Tuesday that it is partnering with drug manufacturer Amneal Pharmaceuticals to produce injectable and oral obesity treatments for clinical trials and commercialization.
Under the deal, Amneal will be Metsera’s preferred supplier in developed markets like the U.S. and Europe, and Amneal will be granted a license to sell Metsera’s drugs in certain emerging markets, including India and some countries in Southeast Asia, Africa, and the Middle East. The companies did not disclose the financial terms of the deal.
Click this link for the original source of this article.
Author: Elaine Chen
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
